Back to top
more

Teva Pharmaceutical Industries (TEVA)

(Delayed Data from NYSE)

$16.01 USD

16.01
12,370,961

+0.30 (1.91%)

Updated Aug 6, 2025 04:00 PM ET

After-Market: $16.05 +0.04 (0.25%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value F Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 35% (161 out of 246)

Industry: Medical - Generic Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

5 Reasons to Invest in Eli Lilly (LLY) Stock Right Now

by Zacks Equity Research

Lily carries a Zacks Rank #2 (Buy).

    Zacks Equity Research

    Teva's Austedo Gets FDA Nod for Huntington Disease Treatment

    by Zacks Equity Research

    Teva Pharmaceutical Industries Ltd. (TEVA) recently announced that the FDA has approved its investigational drug, Austedo (deutetrabenazine) tablets for the treatment of chorea associated with Huntington disease (HD).

      Zacks Equity Research

      Allergan Acne Candidate Meets Endpoints in Phase III Studies

      by Zacks Equity Research

      Allergan plc (AGN) in collaboration with Paratek Pharmaceuticals, Inc. (PRTK) has announced positive results from two phase III studies on sarecycline

        Zacks Equity Research

        Teva Pharma Denies Rumors of Global Workforce Reduction

        by Zacks Equity Research

        According to recent reports, Teva Pharmaceutical Industries Ltd (TEVA) is likely lay off almost 11% of its global workforce to cut costs and improve growth prospects.

          Zacks Equity Research

          Allergan's Restasis Now Available in Multidose Bottle in U.S.

          by Zacks Equity Research

          Allergan plc (AGN) recently announced that its marketed drug Restasis (cyclosporine ophthalmic emulsion) 0.05% is now available in multidose bottles in the U.S.

            Zacks Equity Research

            Allergan's Dermal Filler for Wrinkle Correction Gets FDA Nod

            by Zacks Equity Research

            Allergan plc (AGN) announced yesterday that the FDA has approved its Juvederm Vollure XC dermal filler for correction of facial wrinkles and folds in adults over the age of 21.

              Zacks Equity Research

              Nektar's Pain Drug Positive in Phase III Study; Shares Gain

              by Zacks Equity Research

              Nektar Therapeutics??? (NKTR) shares surged 42.6% after the company announced positive results from a phase III efficacy study evaluating its investigational candidate, NKTR-181, in patients with moderate to severe chronic low back pain.

                Zacks Equity Research

                AstraZeneca (AZN) Gets Another CRL for ZS-9; Inks COPD Deal

                by Zacks Equity Research

                London based AstraZeneca plc (AZN) received a second Complete Response Letter (CRL) from the FDA for its new drug application (NDA) for investigational drug ZS-9.

                  Zacks Equity Research

                  Teva Launches Authorized Generic of Allergan's Minastrin

                  by Zacks Equity Research

                  Teva Pharmaceutical Industries Ltd. (TEVA) recently launched an authorized generic version of Allergan plc???s (AGN) oral contraceptive, Minastrin 24 Fe1, in the U.S.

                    Zacks Equity Research

                    What's Driving Lilly's (LLY) Shares after 2016 Decline?

                    by Zacks Equity Research

                    After a rather difficult 2016, share price of pharma giant, Eli Lilly & Company (LLY) has picked up in 2017.

                      Zacks Equity Research

                      Teva (TEVA) Tops on Q4 Earnings, Maintains 2017 Guidance

                      by Zacks Equity Research

                      Teva Pharmaceutical Industries Ltd. (TEVA) reported fourth-quarter 2016 earnings of $1.34 per share (including equity compensation expenses), which beat the Zacks Consensus Estimate of $1.28.

                        Zacks Equity Research

                        Teva (TEVA) Tops Q4 Earnings & Sales Estimates; Shares Up

                        by Zacks Equity Research

                        Teva???s fourth quarter earnings (including equity compensation expenses), came in at $1.34 per share, beating consensus estimates of $1.32.

                          David Bartosiak headshot

                          Bartosiak: Trading Teva Pharmaceutical's (TEVA) Earnings with Options

                          by David Bartosiak

                          Join David Bartosiak to see his thoughts on Teva Pharma (TEVA) ahead of their earnings announcement, and he'll give us real time insight on how to play the options market.

                            Kinjel Shah headshot

                            Allergan (AGN) Tops Q4 Earnings; 2017 Sales View Upbeat

                            by Kinjel Shah

                            Allergan plc's (AGN) fourth-quarter 2016 earnings came in at $3.90 per share, beating the Zacks Consensus Estimate of $3.79 by 2.9%.

                              Zacks Equity Research

                              Teva (TEVA) Q4 Earnings: What's in Store for the Stock?

                              by Zacks Equity Research

                              Teva Pharmaceutical Industries Ltd. (TEVA) will be reporting fourth-quarter 2016 and full-year earnings on Feb 13, before the market opens.

                                Zacks Equity Research

                                Teva: Vigodman Steps Down, Peterburg Hired as Interim CEO

                                by Zacks Equity Research

                                Teva Pharmaceutical Industries Ltd. (TEVA) recently announced that its present chief executive officer (CEO), Erez Vigodman, is stepping down.

                                  Zacks Equity Research

                                  Dr. Reddy's (RDY) Earnings & Revenues Decline Y/Y in Q3

                                  by Zacks Equity Research

                                  Dr. Reddy's Laboratories Ltd. (RDY) reported third-quarter fiscal 2017 earnings per American Depositary Share (ADS) of 42 cents, down 16% year over year.

                                    Zacks Equity Research

                                    Allergan (AGN) Q4 Earnings: What's in Store for the Stock?

                                    by Zacks Equity Research

                                    Allergan plc (AGN) will be reporting fourth-quarter 2016 earnings on Feb 8, before the market opens. Last quarter, the company delivered a negative earnings surprise of 7.00%.

                                      Zacks Equity Research

                                      Momenta Says District of Delaware Invalidates Teva's MS Drug

                                      by Zacks Equity Research

                                      Shares of Momenta Pharmaceuticals, Inc. (MNTA) shot up 25.2% after Mylan N.V. (MYL) announced that the United States District Court for the District of Delaware has issued a decision in favor of the latter .

                                        Zacks Equity Research

                                        Mylan (MYL) Gets Favorable Verdict for Copaxone in the US

                                        by Zacks Equity Research

                                        Mylan N.V. (MYL) announced that the United States District Court for the District of Delaware has issued a decision in favor of the company pertaining to claims related to Teva Pharmaceutical's (TEVA) Copaxone 40mg/mL.

                                          Zacks Equity Research

                                          Allergan (AGN) Avycaz Label to Include New Phase III Data

                                          by Zacks Equity Research

                                          Allergan plc (AGN) announced that its supplemental new drug application (sNDA) for antibiotic Avycaz has been approved by the FDA. Allergan is looking to include new data from two phase III trials, RECAPTURE and REPRISE, in the drug???s label.

                                            Zacks Equity Research

                                            Will Eli Lilly's (LLY) Earnings Surpass Estimates in Q4?

                                            by Zacks Equity Research

                                            We expect Eli Lilly and Company (LLY) to beat expectations when it reports fourth-quarter and full-year 2016 earnings results on Jan 31, before market opens.

                                              Zacks Equity Research

                                              Teva's (TEVA) Pain Drug Vantrela ER Receives FDA Approval

                                              by Zacks Equity Research

                                              Teva Pharmaceutical Industries Ltd. (TEVA) announced that the FDA has approved Vantrela ER for the treatment of pain which is severe enough to require daily, around-the-clock, long-term opioid treatment.

                                                Zacks Equity Research

                                                Lilly to Boost Migraine Pipeline with $960M CoLucid Buyout

                                                by Zacks Equity Research

                                                Eli Lilly and Company (LLY) announced that it plans to buy Cambridge, MA-based biotech firm CoLucid Pharmaceuticals, Inc. (CLCD) for approximately $960 million in cash.

                                                  Zacks Equity Research

                                                  Lilly-Incyte Rheumatoid Arthritis Drug PDUFA Date Extended

                                                  by Zacks Equity Research

                                                  Eli Lilly and Company (LLY) and Incyte Corporation (INCY) announced that the FDA has extended the time to review the company's NDA for baricitinib for the treatment of rheumatoid arthritis (RA).